Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
NCT06025630

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Led by University of North Texas Health Science Center · Updated on 2025-03-28

70

Participants Needed

1

Research Sites

280 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.

CONDITIONS

Official Title

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years
  • No use of tobacco or nicotine products within the past 6 months
  • Systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg at screening
  • Normal 12-lead ECG verified by a board-certified physician
  • Normal clinical exam results reviewed by a board-certified physician
  • Body mass index (BMI) less than 35 unless having an athletic or muscular build
  • For females: a negative pregnancy test before sessions unless post-menopausal
Not Eligible

You will not qualify if you...

  • Age outside 18 to 80 years
  • Body mass index (BMI) over 35 unless athletic or muscular
  • Any tobacco or nicotine use within the last 6 months
  • Positive pregnancy test
  • Females with irregular menstrual cycles or currently breastfeeding
  • Use of continuously releasing hormonal contraceptives
  • Weight less than 80 pounds
  • Use of medications or supplements affecting vascular function not cleared prior to study
  • Use of beta blockers or daily bronchodilators
  • Use of anti-coagulant therapy
  • Implanted medical devices like pacemakers
  • History of thyroid hormone-related diseases
  • Current hormone replacement therapy
  • HbA1c greater than 5.6
  • Resting systolic blood pressure below 100 mmHg or above 140 mmHg, or diastolic above 90 mmHg
  • Abnormal ECG or uncontrolled heart rhythm causing symptoms
  • History of cerebrovascular abnormalities or atherosclerosis of carotid arteries
  • Recent concussion or loss of consciousness within 30 days
  • Autonomic dysfunction disorders
  • Respiratory illnesses including chronic asthma or COPD
  • History of anaphylaxis or allergies to study materials
  • Severe needle phobia or latex allergy
  • Recent blood donation within 60 days
  • Blood clotting disorders or family history of clots
  • History of alcohol or drug abuse affecting study participation
  • History of mastectomy
  • History of methemoglobinemia
  • Current anemia or fever
  • Use of PDE3 inhibitors or sGC stimulators without willingness to withhold
  • Current cancer diagnosis
  • Recent cardiac surgery or cardiac events
  • Diagnosis of neurological disease or cognitive dysfunction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of North Texas Health Science Center

Fort Worth, Texas, United States, 76107

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here